Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
News|Articles|May 6, 2024
SLIDESHOW: Showcasing Melanoma Research at the 56th Annual ACMS Meeting
Author(s)Lauren Buchanan, MA, Managing Editor
Dozens of investigators shared findings to advance care in patients with melanoma during Mohs micrographic surgery.
Advertisement
References
- Badin D, Salem I, Feng J, et al.Analyzing rate of recurrences and new primary melanotic malignancies post melanoma in situ diagnosis: findings from a single-center study. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.
- Juhasz M, Gharavi N. Cutaneous melanoma upstaging during Mohs micrographic surgery. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.
- Read C, Armstrong A. Factors that impact patients’ satisfaction with their dermatological surgeons: a population study among u.s. adults with melanoma and non-melanoma cutaneous cancers who underwent a surgical procedure. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.
- Moody B, Sudhaman S, Ferguson J, et al. Feasibility of using a tumor-informed circulating tumor DNA (ctDNA) test for clinical decision-making in patients with resectable stage II/III melanoma. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.
- Asamoah E, Demer A, Vidal N, et al. Immunohistochemistry-assisted Mohs surgery for treatment of invasive eyelid and periorbital cutaneous melanoma: oncologic and reconstructive outcomes. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.
- DaCunha M, Coldiron B, Tassavor M, Bland M. Improving melanoma reporting adherence: the melanoma reporting model. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.
- Campbell E, Reinhart J, Proffer S, et al. Incidence and mortality trends of primary cutaneous melanoma: a 50-year population-based study. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.
- Freeman S, Carr D, Shahwan K, Latour E, Leitenberger J. Margin assessment in Mohs for melanoma: evaluation of interrater and intrarater reliability. Poster presented at: 56th Annual ACMS Meeting. May 2-5, 2024; Phoenix, AZ.
Advertisement
Related to this article
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.
The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
2
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
3
Avoiding Common Mistakes When Escalating Therapy in Psoriasis
4
FDA Revises TB Evaluation Guidance for SKYRIZI
5